Histopathologic diagnosis of brain metastases: current trends in management and future considerations
出版年份 2016 全文链接
标题
Histopathologic diagnosis of brain metastases: current trends in management and future considerations
作者
关键词
Brain metastases, Anatomopathology, Immunohistochemistry, Molecular biology, Markers, Targeted therapies
出版物
Brain Tumor Pathology
Volume 34, Issue 1, Pages 8-19
出版商
Springer Nature
发表日期
2016-11-23
DOI
10.1007/s10014-016-0275-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.
- (2017) S. Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Cancer, Version 3.2014
- (2017) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion–Positive Metastatic Non–Small-Cell Lung Cancer
- (2016) Gerald S. Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Immunotherapy for the Treatment of Brain Metastases
- (2016) Justine V. Cohen et al. Frontiers in Oncology
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
- (2015) Keith M. Kerr et al. Journal of Thoracic Oncology
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of RAS family members confers resistance to ROS1 targeting drugs
- (2015) Marilisa Cargnelutti et al. Oncotarget
- Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms
- (2015) George J. Burghel et al. Biomed Research International
- Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases
- (2015) Anna S Berghoff et al. OncoImmunology
- Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
- (2014) S. M. Swain et al. ANNALS OF ONCOLOGY
- BRAF alterations in brain tumours
- (2014) Anna Sophie Berghoff et al. CURRENT OPINION IN NEUROLOGY
- Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin
- (2014) Moon-Young Kim et al. HISTOPATHOLOGY
- ROS1 translocations and amplifications in lung cancer brain metastases
- (2014) Matthias Preusser et al. JOURNAL OF NEURO-ONCOLOGY
- Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer
- (2014) Leo S. Payne et al. Journal of Thoracic Oncology
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
- (2014) Huiyong Sun et al. PLoS Computational Biology
- Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer
- (2013) Issa J. Dahabreh et al. ANNALS OF INTERNAL MEDICINE
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update
- (2013) Nelson G. Ordóñez HUMAN PATHOLOGY
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
- (2013) Oliver Gautschi et al. Journal of Thoracic Oncology
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
- (2013) Kurtis D. Davies et al. PLoS One
- Challenging resistance mechanisms to therapies for metastatic melanoma
- (2013) Lucio Tentori et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- In Search of the Ideal Immunopanel to Distinguish Metastatic Mammary Carcinoma From Primary Lung Carcinoma
- (2013) Kathy R. Kawaguchi et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Brain metastases: pathobiology and emerging targeted therapies
- (2012) Matthias Preusser et al. ACTA NEUROPATHOLOGICA
- Characterization of the inflammatory response to solid cancer metastases in the human brain
- (2012) Anna Sophie Berghoff et al. CLINICAL & EXPERIMENTAL METASTASIS
- A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis
- (2012) T. Joyce et al. CURRENT CANCER DRUG TARGETS
- Brain metastases as the first symptom of lung cancer: a clinical study from an Asian medical center
- (2012) Jia Jin et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR mutation status in brain metastases of non-small cell lung carcinoma
- (2012) Fanny Burel-Vandenbos et al. JOURNAL OF NEURO-ONCOLOGY
- Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
- (2012) Leow Pay Chin et al. Journal of Thoracic Oncology
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- (2012) Andrew J. Weickhardt et al. Journal of Thoracic Oncology
- Cancer classification using the Immunoscore: a worldwide task force
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- The immune score as a new possible approach for the classification of cancer
- (2012) Jérôme Galon et al. Journal of Translational Medicine
- RET, ROS1 and ALK fusions in lung cancer
- (2012) Kengo Takeuchi et al. NATURE MEDICINE
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
- (2011) Eitan Amir et al. CANCER TREATMENT REVIEWS
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
- (2011) A. M. Brufsky et al. CLINICAL CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
- (2011) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
- (2010) Jennifer L. Clarke et al. JOURNAL OF NEURO-ONCOLOGY
- Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
- (2010) Ryoichi Onozato et al. Journal of Thoracic Oncology
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
- (2009) Tsuyoshi Takahashi et al. ANNALS OF SURGICAL ONCOLOGY
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Defining prognosis for women with breast cancer and CNS metastases by HER2 status
- (2008) S. Dawood et al. ANNALS OF ONCOLOGY
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- KIT Gene Mutations and Copy Number in Melanoma Subtypes
- (2008) C. Beadling et al. CLINICAL CANCER RESEARCH
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- (2008) J. P. Koivunen et al. CLINICAL CANCER RESEARCH
- Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
- (2008) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Central Nervous System Metastases in HER-2-Overexpressing Metastatic Breast Cancer: A Treatment Challenge
- (2008) H.-J. Stemmler et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More